| dc.contributor.author | Sezer, A. | |
| dc.contributor.author | Tural, D. | |
| dc.contributor.author | Korkmaz, T. | |
| dc.contributor.author | Paydas, S. | |
| dc.contributor.author | Yilmaz, C. | |
| dc.contributor.author | Turna, H. | |
| dc.contributor.author | Beypinar, I. | |
| dc.contributor.author | Cinkir, H. Yesil | |
| dc.contributor.author | Okutur, K. | |
| dc.contributor.author | Erman, M. | |
| dc.contributor.author | Cabuk, D. | |
| dc.contributor.author | Isikdogan, A. | |
| dc.contributor.author | Demirkazik, A. | |
| dc.contributor.author | Karaoglu, A. | |
| dc.contributor.author | Yazilitas, D. | |
| dc.contributor.author | ŞENLER, FİLİZ ÇAY | |
| dc.contributor.author | Yumuk, P. F. | |
| dc.contributor.author | Coskun, H. | |
| dc.contributor.author | Yildiz, I. | |
| dc.contributor.author | Oztop, I. | |
| dc.contributor.author | Aydin, K. | |
| dc.contributor.author | Kaplan, M. | |
| dc.contributor.author | Meydan, N. | |
| dc.contributor.author | Olmez, O. F. | |
| dc.contributor.author | Ozyilkan, O. | |
| dc.contributor.author | Seber, S. | |
| dc.contributor.author | Arslan, C. | |
| dc.contributor.author | Sendur, M. A. | |
| dc.contributor.author | Cicin, I. | |
| dc.contributor.author | Eralp, Y. | |
| dc.contributor.author | Kilickap, S. | |
| dc.contributor.author | Demirci, U. | |
| dc.contributor.author | Bugdayci, F. | |
| dc.date.accessioned | 2021-03-03T07:58:08Z | |
| dc.date.available | 2021-03-03T07:58:08Z | |
| dc.date.issued | 2019 | |
| dc.identifier.citation | Kilickap S., Demirci U., Bugdayci F., Tural D., Korkmaz T., Paydas S., Yilmaz C., Turna H., Sezer A., Cinkir H. Y. , et al., "Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey", JOURNAL OF THORACIC ONCOLOGY, cilt.14, sa.10, 2019 | |
| dc.identifier.issn | 1556-0864 | |
| dc.identifier.other | vv_1032021 | |
| dc.identifier.other | av_14e52fe5-9552-483e-9899-64b6dfdcffbf | |
| dc.identifier.uri | http://hdl.handle.net/20.500.12627/19426 | |
| dc.identifier.uri | https://doi.org/10.1016/j.jtho.2019.08.1166 | |
| dc.language.iso | eng | |
| dc.subject | Klinik Tıp | |
| dc.subject | ONKOLOJİ | |
| dc.subject | SOLUNUM SİSTEMİ | |
| dc.subject | Tıp | |
| dc.subject | Sağlık Bilimleri | |
| dc.subject | Dahili Tıp Bilimleri | |
| dc.subject | Göğüs Hastalıkları ve Allerji | |
| dc.subject | İç Hastalıkları | |
| dc.subject | Onkoloji | |
| dc.subject | Klinik Tıp (MED) | |
| dc.title | Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey | |
| dc.type | Makale | |
| dc.relation.journal | JOURNAL OF THORACIC ONCOLOGY | |
| dc.contributor.department | Hacettepe Üniversitesi , , | |
| dc.identifier.volume | 14 | |
| dc.identifier.issue | 10 | |
| dc.contributor.firstauthorID | 269496 | |
